Amélie Darlix

19PUBLICATIONS
49CO-AUTHORS
Predictive and prognostic markersPacific Peoples midwifery and paediatricsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 12, 2026
Modeling tumor volume trajectory and outcome identifies 3 distinct response classes in lower-grade IDH-mutant glioma receiving first-line chemotherapy.

|Feb 16, 2026
Beyond proof-of-concept: Validating robust automated diffuse lower-grade glioma segmentation for clinical applications in longitudinal follow-up.

Jeremy Deverdun, Guillaume Clain, Margaux Verdier

|May 12, 2025
Integrated early palliative care for patients with newly diagnosed glioblastoma: The GLIOSUPPORT feasibility study.

Michel Fabbro, Muriel Thomaso, Amélie Darlix

|Jan 08, 2025
Who will benefit from vorasidenib? Review of data from the literature and open questions.

Amélie Darlix, Matthias Preusser, Shawn L Hervey-Jumper

|Aug 02, 2024
Descriptive epidemiology of 399 histologically confirmed newly diagnosed meningeal solitary fibrous tumours and haemangiopericytomas in France: 2006-2015.

Charles Champeaux Depond, Sonia Zouaoui, Amélie Darlix

|Jul 01, 2024
Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: A feasibility study.

Amélie Darlix, Maëva Monnier, Florence Castan

Pageof 4

Frequent Collaborators

4 joint publications

Estelle Guerdoux-Ninot

4 joint publications

Luc Bauchet

4 joint publications

Valérie Rigau

3 joint publications

Hugues Duffau